On July 20, Sino Biopharmaceutical rose 3.01% in regular trading, trading at 5.16 HKD/share, with turnover of 74.11 million HKD. The broader pharmaceutical sector rallied strongly, with Sunshine Pharma up 5.36%, CSPC Pharma up 4.44%, Hansoh Pharma up 4.40%, Hengrui Pharma up 4.36%, and Luye Pharma up 4.37%.

The rally follows a series of recent positive developments for the company. On July 14, its subsidiary Beijing Tide Pharmaceutical's novel drug TRD205, an AT2R antagonist targeting chronic post-surgical neuropathic pain, received Breakthrough Therapy Designation from the CDE based on positive Phase II data. On July 10, the IDH1 inhibitor TQB3454 NDA for advanced biliary tract cancer was accepted. On July 8, the company signed an exclusive licensing agreement with AstraZeneca for TQC3721, a PDE3/4 inhibitor for COPD, with total consideration up to USD 1.9 billion including a USD 200 million upfront payment. The same day, it deepened its strategic partnership with GSK in respiratory. Multiple brokerages maintain buy ratings, with target prices of HKD 8.70 and HKD 7.70.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)